Abstract library

14 results for "multi-center".
#1346 A Nation-Wide Retrospective Epidemiological Study of Gastroenteropancreatic Neuroendocrine Neoplasms in China
Introduction: Representative data on the gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) in Chinese patients is rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Zhang Yu-Qing
#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan
Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD,PhD Yasunari Sakamoto
Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, ...
Keywords: Streptozocin, pNETs
#705 A Multi-Center Retrospective Evaluation of Neuroendocrine Tumors (Anatolian Society of Medical Oncology Group Study)
Introduction: Neuroendocrine tumors (NETs) are uncommon malignancies.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D Halit Karaca
Authors: Karaca H, Erol O, Ulas A, Demirci U, ...
#1498 Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-center, Open-label, Dose-escalation Study
Introduction: PAS, a next generation SSA, is investigated to determine the maximum tolerated dose (MTD) in pts with advanced NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD James Yao
Authors: Yao J, Chan J, Mita A, Kundu M, ...
Keywords: Pasireotide, MTD
#2087 Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy of advanced NETs. The efficacy controlling hormone release and tumor growth together with the favorable toxicity profile have positioned SSAs as upfront therapy. Despite of second-line therapies including targeted agents, chemotherapy and radiolabeled peptides have demonstrated activity controlling tumor growth, the less favorable toxicity profiles become a usual discussion with patients (pts) to preserve the quality of life (QoL). Additionally, from concordant flow of evidences clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products. APOC is a new controlled release ready-to-use convenient therapeutic, designed to cover specifically these clinical unmet needs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Jaume Capdevila
#125 Ectopic hormone secreting phaeochromocytoma: A francophone observational study
Introduction: Ectopic hormone-secreting phaeochromocytomas are rare and only small reports of 1-2 cases exist in the literature. In the past, this condition has been linked with increased malignancy, familial syndromes and ACTH secretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Bruno Carnaille
#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Keywords: Lung NETs, lanreotide
#1695 A Multicenter 10-Year Clinical Epidemiological Study of Rectal Neuroendocrine Tumors in China
Introduction: Few data can be available for rectal neuroendocrine tumors (NETs) in China
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: professor Fan Jinhu
#1746 Clinical Outcomes in Small Neuroendocrine Tumours Treated with Intestinal Surgery in Tertiary Centre
Introduction: Patients with Small Bowel Neuroendocrine Tumours (SBNET) may require small bowel surgery either as an emergency or electively.Robust data from Tertiary Referral Centres (TRC) are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Georgios Demetriou
#1803 Type 3 Gastric Neuroendocrine Neoplasms: Relationship Between Tumor Size, Ki67 and Clinical Outcome
Introduction: Sporadic type 3 gNENs are usually malignant with high metastatic potential, mostly large, with a high grade histology. However, little is known on the relationship between tumor size, proliferative index Ki67, and clinical outcome
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Francesco Panzuto